Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
clinical trials
eli lilly
indiana blog main
indiana top stories
life sciences
national blog main
raleigh-durham blog main
raleigh-durham top stories
4
×
teva pharmaceutical
4
×
amgen
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
fremanezumab
migraine research foundation
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
calcitonin gene-related peptide
chronic migraine
eptinezumab
erenumab
galcanezumab
lasmiditan
What
approval
4
×
drug
new
fda
migraine
won
class
companies
decades
acute
addresses
amgen
arguments
big
bio
biogen’s
biopharmaceutical
candidates
causes
commercialized
competitors
condition
convo
developed
drugs
earlier
eli
failures
friday
gets
giant
giving
head
lasmiditan
lilly
lilly’s
littered
make
medication
medicines
Language
unset
Current search:
approval
×
" raleigh-durham top stories "
×
" teva pharmaceutical "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines